Document is current

Article History

Received: 27 October 2024

Accepted: 4 February 2025

First Online: 10 February 2025

Declarations

:

: During the preparation of this work the author(s) used Chat-GPT 4o for English proofreading and spell check. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

: The protocol was approved by Institutional Review Board in Osaka International Cancer Institute in accordance with the Constitution of Japan, the Act on the Protection of Personal Information. The institutional ethics committee approved the acquisition of all samples and all methods conducted. Informed consent statement for case reporting and publishing was obtained from the participants and their families. The patient and their family provided consent for the publication of anonymized data in an open-access journal. All data have been anonymized.

: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Kunimasa reports honoraria for lecture from AstraZeneca, Chugai Pharma and Novartis; Dr. Nishino reports receiving grants from Ono, TAIHO, MSD, AbbVie, DAIICHI SANKYO, Amgen, Eisai, Sanofi, Janssen, Novartis, Pfizer, Eli Lilly, Merck, Takeda, Chugai, Merus and personal fees from AstraZeneca, Chugai, Nippon Boehringer Ingerheim, Eli Lilly, Roche, Novartis, Pfizer, Merck, Janssen, Bristol Myers Squibb and Nippon Kayaku. Dr. Aohara declares no conflict of interest.